Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis - Takeaways - MDSpire

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

  • By

  • Philipp Berning

  • Markus Maulhardt

  • Hristo Boyadzhiev

  • Anca-Maria Albici

  • Snjezana Janjetovic

  • Anna Ossami Saidy

  • Christian Schultze-Florey

  • Simon Call

  • Friedrich Stölzel

  • Annamaria Brioli

  • Michael Daskalakis

  • Juliane Knust

  • Justin Hasenkamp

  • Rebecca Wurm-Kuczera

  • Alexander Pohlmann

  • Matthias Stelljes

  • Cyrus Khandanpour

  • Ulrike Bacher

  • Amelie Boquoi

  • Florian H. Heidel

  • Hans Christian Reinhardt

  • Gerald Wulf

  • Natalie Schub

  • Bastian von Tresckow

  • Georg Lenz

  • Thomas Pabst

  • Evgenii Shumilov

  • June 2, 2026

  • 0 min

Share

  • 1

    The study evaluated the efficacy and safety of CAR-T therapies in patients with relapsed/refractory multiple myeloma, focusing on age-related differences.

  • 2

    A total of 148 patients were enrolled, with 35.1% aged 70 years or older, highlighting the underrepresentation of older adults in CAR-T clinical trials.

  • 3

    Elderly patients had significantly higher comorbidity and frailty compared to younger patients, which may impact treatment outcomes.

  • 4

    The overall response rate was higher in older patients at 94.1% compared to 78.7% in younger patients, with a notable increase in complete response rates.

  • 5

    Non-relapse mortality was higher in older patients at 17.1%, emphasizing the need for structured follow-up and preventive strategies in this population.

Original Source(s)

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

  • by Philipp Berning, Markus Maulhardt, Hristo Boyadzhiev, Anca-Maria Albici, Snjezana Janjetovic, Anna Ossami Saidy, Christian Schultze-Florey, Simon Call, Friedrich Stölzel, Annamaria Brioli, Michael Daskalakis, Juliane Knust, Justin Hasenkamp, Rebecca Wurm-Kuczera, Alexander Pohlmann, Matthias Stelljes, Cyrus Khandanpour, Ulrike Bacher, Amelie Boquoi, Florian H. Heidel, Hans Christian Reinhardt, Gerald Wulf, Natalie Schub, Bastian von Tresckow, Georg Lenz, Thomas Pabst, Evgenii Shumilov

  • June 2, 2026

Related Content

Ultraviolet radiation as a double-edged regulator of melanocyte function in vitiligo therapy and melanoma carcinogenesis

Multidimensional exposure architecture shapes vaping-associated transcriptomic dysregulation in oral epithelium

HPV-specific innovations and controversies in therapeutic strategies for HPV-associated oropharyngeal carcinoma